TP53 and myelodysplastic syndrome: A notable phase Ib/II study showcased that the combination of PRIMA‐1met and azacytidine achieved a high rate of clinical response and molecular remissions in patients with p53 mutant myelodysplastic syndromes (MDS) or oligoblastic AML [61].